FDA greenlights Biocon’s Liraglutide for chronic weight management
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
Nadda underlined that India’s policy framework is aligned with this transformation
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
Subscribe To Our Newsletter & Stay Updated